Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
RocheSwiss diversified pharma. Carmot acquisition (December 2023, $2.7B) brought CT-388 (about 23% placebo-adjusted weight loss at 48 weeks Phase 2), CT-996 oral, and CT-868. Zealand licensing deal ($1.65B) added petrelinitide amylin program.
Semi-annual breakdown of revenue into costs and profit
H1 2006 — H2 2025
How revenue flows through costs to become profit
Assets = Liabilities + Equity
H1 2016 — H2 2025
Cash position and cash generation
H1 2016 — H2 2025